CHEPLAPHARM Arzneimittel GmbH
CHEPLAPHARM Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Greifswald, Germany. Founded in 1986, the company has established itself as a leader in the development, production, and distribution of high-quality generic and specialty pharmaceuticals. With a strong presence across Europe and expanding operations in various international markets, CHEPLAPHARM focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. Notable achievements include strategic partnerships and a robust pipeline of generics that enhance patient access to essential medications. CHEPLAPHARM's dedication to excellence positions it as a trusted name in the pharmaceutical landscape, continually striving to improve health outcomes worldwide.
DitchCarbon Score
How does CHEPLAPHARM Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHEPLAPHARM Arzneimittel GmbH's score of 15 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
CHEPLAPHARM Arzneimittel GmbH's reported carbon emissions
In 2023, CHEPLAPHARM Arzneimittel GmbH reported carbon emissions of approximately 130,900 kg CO2e from Scope 1, which includes 33,600 kg CO2e from mobile combustion and 95,000 kg CO2e from process emissions. Additionally, the company recorded about 16,000 kg CO2e in Scope 2 emissions, primarily from purchased heat. In 2022, the total emissions were approximately 198,000 kg CO2e for Scope 2 and 111,000 kg CO2e for Scope 1, indicating a slight increase in Scope 1 emissions in 2023. The total market-based emissions for Scope 1 and 2 combined were not specified for 2023. Despite these figures, CHEPLAPHARM has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). The absence of defined reduction strategies suggests a need for further commitment to climate action within the pharmaceutical industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2021 | 2022 | |
|---|---|---|
| Scope 1 | - | 000,000 |
| Scope 2 | 323,000 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CHEPLAPHARM Arzneimittel GmbH is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
